MedTrace Logo

CRUZ Tunisia-Multivessel Registry

NCT06663696 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-04-27

No results posted yet for this study

Summary

The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).

Conditions

  • Patient Population With Multivessel Disease

Interventions

DEVICE

Supraflex Cruz Sirolimus-eluting Coronary Stent System

Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent

Sponsors & Collaborators

  • Sahajanand Medical Technologies Limited

    lead INDUSTRY

Principal Investigators

  • Prof. Nadhem HAJLAOUI · University of Tunis El Manar, Tunisia

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-11-30
Completion
2028-05-31

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663696 on ClinicalTrials.gov